Latest Insider Transactions at Alto Neuroscience, Inc. (ANRO)
This section provides a real-time view of insider transactions for Alto Neuroscience, Inc. (ANRO). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Alto Neuroscience, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Alto Neuroscience, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jul 10
2024
|
Adam Savitz CHIEF MEDICAL OFFICER |
BUY
Open market or private purchase
|
Indirect |
2,931
+6.85%
|
$38,103
$13.22 P/Share
|
|
Jul 09
2024
|
Adam Savitz CHIEF MEDICAL OFFICER |
BUY
Open market or private purchase
|
Indirect |
12,069
+13.37%
|
$144,828
$12.84 P/Share
|
|
Mar 28
2024
|
Nicholas Conrad Smith CHIEF FINANCIAL OFFICER |
BUY
Open market or private purchase
|
Direct |
6,150
+10.59%
|
$98,400
$16.18 P/Share
|
|
Mar 01
2024
|
Amit Etkin PRESIDENT AND CEO |
BUY
Grant, award, or other acquisition
|
Direct |
34,711
+2.72%
|
-
|
|
Mar 01
2024
|
Nicholas Conrad Smith CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
19,153
+48.04%
|
-
|
|
Feb 06
2024
|
Apeiron Investment Group Ltd. |
BUY
Conversion of derivative security
|
Indirect |
674,658
+50.0%
|
-
|
|
Feb 06
2024
|
Apeiron Investment Group Ltd. |
BUY
Conversion of derivative security
|
Direct |
251,881
+50.0%
|
-
|
|
Feb 06
2024
|
Alpha Wave Global, LP > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
600,000
+13.93%
|
$9,600,000
$16.0 P/Share
|
|
Feb 06
2024
|
Alpha Wave Global, LP > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
3,107,757
+38.46%
|
-
|
|
Feb 06
2024
|
Nicholas Conrad Smith CHIEF FINANCIAL OFFICER |
BUY
Open market or private purchase
|
Direct |
1,563
+50.0%
|
$25,008
$16.0 P/Share
|
|
Feb 06
2024
|
Gwill York |
BUY
Conversion of derivative security
|
Direct |
23,917
+50.0%
|
-
|
|
Feb 06
2024
|
Po Yu (Jeff) Chen |
BUY
Conversion of derivative security
|
Direct |
47,709
+32.52%
|
-
|
|
Feb 06
2024
|
Amit Etkin PRESIDENT AND CEO |
BUY
Open market or private purchase
|
Direct |
3,125
+0.26%
|
$50,000
$16.0 P/Share
|
|
Feb 06
2024
|
Amit Etkin PRESIDENT AND CEO |
BUY
Conversion of derivative security
|
Direct |
11,777
+0.97%
|
-
|
|
Feb 06
2024
|
Adam Savitz CHIEF MEDICAL OFFICER |
BUY
Open market or private purchase
|
Indirect |
17,000
+40.62%
|
$272,000
$16.0 P/Share
|
|
Feb 06
2024
|
Adam Savitz CHIEF MEDICAL OFFICER |
BUY
Conversion of derivative security
|
Indirect |
7,851
+50.0%
|
-
|
|
Feb 06
2024
|
Christopher Nixon Cox |
BUY
Conversion of derivative security
|
Indirect |
715,653
+32.52%
|
-
|